Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28338084 | 0.81 | MEN1 (0.46) | MEN1KMT2ARAB9AALDH1A1LMNA | |
| SCHEMBL4141360 | 0.79 | KMT2A (0.38) | MEN1KMT2AAPPPKMALDH1A1 | |
| SCHEMBL28734034 | 0.77 | ERN1 (0.34) | MEN1KMT2AAPPPKMALDH1A1 | |
| SCHEMBL31025937 | 0.75 | ALDH1A1 (0.38) | MEN1KMT2AAPPALDH1A1KDM4E | |
| SCHEMBL10934015 | 0.72 | ERN1 (0.51) | MEN1KMT2ARAB9AALDH1A1L3MBTL1 | |
| SCHEMBL24106777 | 0.72 | RXRA (0.45) | MEN1KMT2ARAB9AALDH1A1RXRA | |
| SCHEMBL547760 | 0.72 | KMT2A (0.42) | MEN1KMT2ARAB9AALDH1A1LMNA | |
| SCHEMBL31493165 | 0.72 | KMT2A (0.42) | MEN1KMT2ARAB9AALDH1A1LMNA | |
| SCHEMBL29613044 | 0.71 | KMT2A (0.43) | MEN1KMT2AAPPALDH1A1LMNA | |
| SCHEMBL7605635 | 0.71 | KMT2A (0.43) | MEN1KMT2AAPPALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718825-B2 | formylating first arylamine compound to form formyl substituted arylamine compound, and acidifying the formyl substituted arylamine compound, in the presence of a solvent and a solid organic catalyst, to convert formyl functional groups into acid functional groups to form an acidified compound | XEROX CORPORATION (US) | 2010-05-18 | — | — | US | disclosed |
| EP-1666449-B1 | Process for arylamine production | XEROX CORP (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20070232830-A1 | formylating first arylamine compound to form formyl substituted arylamine compound, and acidifying the formyl substituted arylamine compound, in the presence of a solvent and a solid organic catalyst, to convert formyl functional groups into acid functional groups to form an acidified compound | XEROX CORPORATION (US) | 2007-10-04 | — | — | US | disclosed |
| US-7227034-B2 | Process for arylamine production | XEROX CORPORATION (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1666449-A1 | Process for arylamine production | Xerox Corporation (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060111583-A1 | Process for arylamine production | XEROX CORPORATION (US) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232830-A1 | formylating first arylamine compound to form formyl substituted arylamine compound, and acidifying the formyl substituted arylamine compound, in the presence of a solvent and a solid organic catalyst, to convert formyl functional groups into acid functional groups to form an acidified compound | AHR, NAT1, MAOA | MEN1 2459/4885KMT2A 256/4885RAB9A 4281/4885 |
| US-20060111583-A1 | Process for arylamine production | AHR, PAH, AADAT | MEN1 3377/4885KMT2A 816/4885RAB9A 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.